EF-41 / KEYNOTE D58 – A Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant With Maintenance TMZ and Pembrolizumab Versus Optune® Concomitant With Maintenance TMZ and Placebo for the Treatment of Newly Diagnosed Glioblastoma

By clinicaltrials.govAugust 16, 2024Updated:August 17, 2024No Comments1 Min Read